解痉通络活血药物对高血压病患者纤溶功能变化的影响

Clinical studies on change of inflammatory factor of hypertension patients treated by blood coagulation

目的了解解痉通络活血药物治疗高血压病患者血清溶栓功能指标的变化情况。方法选取76例高血压病患者随机分为治疗组1和治疗组2两组,每组38例,治疗组2单纯给予常规西医治疗,治疗组1在常规西医治疗的基础上加用解痉通络活血药物治疗2个月,于治疗前后对两组血清P-选择素(Ps)、组织型纤溶酶原激活物(t-PA)、纤溶酶原激活物抑制物(PAI)和血管性血友病因子(vWF)水平分别进行检测,并与30例健康体检者比较。结果治疗组1治疗前血清Ps、PAI和vWF水平高于对照组(P<0.01),治疗后差异无统计学意义(P>0.05);治疗前血清tPA水平低于对照组(P<0.01),治疗后差异无统计学意义(P>0.05)。治疗组2治疗前血清Ps、PAI和vWF水平均高于对照组(P<0.01),治疗后血清Ps、PAI和vWF水平虽有下降,但仍高于对照组(P<0.01);治疗前血清tPA水平低于对照组(P<0.01),治疗后血清tPA水平水平虽有提高,但仍低于对照组(P<0.01)。结论解痉通络活血药物对高血压病患者的溶栓功能紊乱有改善作用。

Objective To explore the changing situation of serum thrombolytic function of hypertension patients treated by blood coagulation. Methods 76 hypertension patients were randomly divided into treatment group I and group 2, with 38 cases in each group. The patients in group 2 were treated by routine western medicine therapy, while the patients in group l were mainly treated by blood coagulation on the basic of routine western medicine therapy for two months. The level of P - selectin serum, tissue type plasminogen activator （tPA）, plasmiuogen activator inhibitor （PAI） and von willebrand disease factor （vWF） of each group were tested before and after the treatment, compared with which of 30 cases in health in body - check. Results The level of Ps, PAI and vWF of group 1 were higher than that of control group before the treatment（ P 〈 0. 01 ）, while there was no statistical significance between them after the treatment （ P 〉 0. 05 ） ; The level of tPA was lower than that of the control group（P 〈0. 01 ）, while there was no statistical significance between them after the treatment（ P 〉 0. 05 ）. The level of Ps, PAl and vWF of group 2 were higher than that of control group before the treatment （ P 〈 0. 01 ）, and the level was still higher than that of control group（ P 〈0. 01 ）, though it got a little bit lower than itself before the treatment; The level of IPA was lower than that of the control group before the treatment（ P 〈0. 01 ） , and the level was still lower than that of the control group after the treatment（ P 〈0. 01 ）, though it got a little bit higher than itself before the treatment. Conclusion There is significant improvement to inhibitor functional disorder of hypertension patients treated by blood coagulation.